Accumulated amyloid-β peptide and hyperphosphorylated tau protein: Relationship and links in Alzheimer's disease

Journal of Alzheimer's Disease

Volumn 16, Issue 1, 2009, Pages 15-27

  Huang, Han Chang ^a,b   Jiang, Zhao Feng ^a,b  

^a BEIJING UNION UNIVERSITY   (China)

^b Beijing United University   (China)

Author keywords

Amyloid peptide (A ); Oxidative stress; PI3K Akt; Tau protein; 7nAChR

Indexed keywords

AMYLOID BETA PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; TAU PROTEIN;

ALZHEIMER DISEASE; CHOLINERGIC NERVE CELL; HOMEOSTASIS; HUMAN; MICROTUBULE; NEURITIS; NEUROFIBRILLARY TANGLE; NEUROPATHOLOGY; NEUROTOXICITY; OXIDATIVE STRESS; PATHOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DEGRADATION; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 58849143335     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2009-0960     Document Type: Review

References (101)

1. Hardy J (2006) Has the amyloid cascade hypothesis for Alzheimer's disease been proved? Curr Alzheimer Res 3, 71-73.
2. Lord A, Kalimo H, Eckman C, Zhang XQ, Lannfelt L, Nilsson LN (2006) The Arctic Alzheimer mutation facilitates early intraneuronal Abeta aggregation and senile plaque formation in transgenic mice. Neurobiol Aging 27, 67-77.
3. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST (2007) Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci 27, 6174-6184.
4. Shimojo M, Sahara N, Murayama M, Ichinose H, Takashima A (2007) Decreased Abeta secretion by cells expressing familial Alzheimer's disease-linked mutant presenilin 1. Neurosci Res 57, 446-453.
5. Zatti G, Burgo A, Giacomello M, Barbiero L, Ghidoni R, Sinigaglia G, Florean C, Bagnoli S, Binetti G, Sorbi S, Pizzo P, Fasolato C (2006) Presenilin mutations linked to familial Alzheimer's disease reduce endoplasmic reticulum and Golgi apparatus calcium levels. Cell Calcium 39, 539-550.
6. Tanzi RE, Bertram L (2005) Twenty years of the Alzheimer's disease amyloid hypothesis: A genetic perspective. Cell 120, 545-555.
7. Curtain CC, Ali F, Volitakis I, Cherny RA, Norton RS, Beyreuther K, Barrow CJ, Masters CL, Bush AI, Barnham KJ (2001) Alzheimer's disease amyloid-beta binds copper and zinc to generate an allosterically ordered membrane-penetrating structure containing superoxide dismutase-like subunits. J Biol Chem 276, 20466-20473.
8. Valko M, Morris H, Cronin MT (2005) Metals, toxicity and oxidative stress. Curr Med Chem 12, 1161-1208.
9. Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3, 205-214.
10. Wenk GL, Parsons CG, Danysz W (2006) Potential role of N-methyl-D-aspartate receptors as executors of neurodegeneration resulting from diverse insults: focus on memantine. Behav Pharmacol 17, 411-424.
11. Wang HY, Lee DH, Davis CB, Shank RP (2000) Amyloid peptide Abeta(1-42) binds selectively and with picomolar affinity to alpha7 nicotinic acetylcholine receptors. J Neurochem 75, 1155-1161.
12. Tagami S, Tsujimoto Y, Akaike A, Takashima A, Hasegawa M, Ishiguro K, Shoji M, Ito N, Kanemaru K, Urakami K, Okochi M, Takeda M (2006) Involvement of apoptosis and cholinergic dysfunction in Alzheimer's disease. Psychogeriatrics 6, S57-S63.
13. Yamamoto H, Yamauchi E, Taniguchi H, Ono T, Miyamoto E (2002) Phosphorylation of microtubule-associated protein tau by Ca2+/calmodulin- dependent protein kinase II in its tubulin binding sites. Arch Biochem Biophys 408, 255-262.
14. Mattson MP (2007) Calcium and neurodegeneration. Aging Cell 6, 337-350.
15. Iqbal K, Grundke-Iqbal I (2005) Metabolic/signal transduction hypothesis of Alzheimer's disease and other tauopathies. Acta Neuropathologica 109, 25-31.
16. Zheng H, Koo EH (2006) The amyloid precursor protein: beyond amyloid. Mol Neurodegener 1, 5.
17. Sisodia SS, Koo EH, Hoffman PN, Perry G, Price DL (1993) Identification and transport of full-length amyloid precursor proteins in rat peripheral nervous system. J Neurosci 13, 3136-3142.
18. Selkoe DJ (1996) Amyloid beta-protein and the genetics of Alzheimer's disease. J Biol Chem 271, 18295-18298.
19. Oddo S, Caccamo A, Shepherd JD, Murphy MP, Golde TE, Kayed R, Metherate R, Mattson MP, Akbari Y, LaFerla FM (2003) Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron 39, 409-421.
20. Billings LM, Oddo S, Green KN, McGaugh JL, LaFerla FM (2005) Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron 45, 675-688.
21. Rajendran L, Honsho M, Zahn TR, Keller P, Geiger KD, Verkade P, Simons K (2006) Alzheimer's disease betaamyloid peptides are released in association with exosomes. Proc Natl Acad Sci U S A 103, 11172-11177.
22. Tanzi RE, Moir RD, Wagner SL (2004) Clearance of Alzheimer's Abeta peptide: the many roads to perdition. Neuron 43, 605-608.
23. Zlokovic BV, Deane R, Sallstrom J, Chow N, Miano JM (2005) Neurovascular pathways and Alzheimer amyloid beta-peptide. Brain Pathol 15, 78-83.
24. Wang DS, Dickson DW, Malter JS (2006) β-Amyloid degradation and Alzheimer's disease. J Biomed Biotechnol 2006, Article ID 58406, 12 pages.
25. Iwata N, Tsubuki S, Takaki Y, Watanabe K, Sekiguchi M, Hosoki E, Kawashima-Morishima M, Lee HJ, Hama E, Sekine-Aizawa Y, Saido TC (2000) Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: suppression leads to biochemical and pathological deposition. Nat Med 6, 143-150.
26. Farris W, Schütz SG, Cirrito JR, Shankar GM, Sun X, George A, Leissring MA, Walsh DM, Qiu WQ, Holtzman DM, Selkoe DJ (2007) Loss of neprilysin function promotes amyloid plaque formation and causes cerebral amyloid angiopathy. Am J Pathol 171, 241-251.
27. Eckman EA, Reed DK, Eckman CB (2001) Degradation of the Alzheimer's amyloid beta peptide by endothelin-converting enzyme. J Biol Chem 276, 24540-24548.
28. Qiu WQ, Walsh DM, Ye Z, Vekrellis K, Zhang J, Podlisny MB, Rosner MR, Safavi A, Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273, 32730-32738.
29. Qiu WQ, Folstein MF (2006) Insulin, insulin-degrading enzyme and amyloid-beta peptide in Alzheimer's disease: review and hypothesis. Neurobiol Aging 27, 190-198.
30. Hu J, Igarashi A, Kamata M, Nakagawa H (2001) Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (Aβ); retards Aβ aggregation, deposition, fibril formation; and inhibits cytotoxicity. J Biol Chem 276, 47863-47868.
31. Hamazaki H (1996) Cathepsin D is involved in the clearance of Alzheimer's beta-amyloid protein. FEBS Lett 396, 139-142.
32. Yamada T, Miyazaki K, Koshikawa N, Takahashi M, Akatsu H, Yamamoto T (1995) Selective localization of gelatinase A, an enzyme degrading beta-amyloid protein, in white matter microglia and in Schwann cells. Acta Neuropathol 89, 199-203.
33. Lee JM, Hu XY, Crick S, Song H, Yin K, Cirrito J, Bateman R, Hsu CY, Xu J, Hsu FF, Turk J, Pappu R, Holtzman DM, Yan P (2006) Matrix metalloproteinase-9 degrades Amyloid-β fibrils in vitro and compact plaques in situ. Alzheimers Dement 2, S89-S89.
34. Backstrom JR, Lim GP, Cullen MJ, Tökés ZA (1996) Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J Neurosci 16, 7910-7919.
35. Qiu WQ, Borth W, Ye Z, Haass C, Teplow DB, Selkoe DJ (1996) Degradation of amyloid beta-protein by a serine protease-alpha2-macroglobulin complex. J Biol Chem 271, 8443-8451.
36. El-Amouri SS, Zhu H, Yu J, Gage FH, Verma IM, Kindy MS (2007) Neprilysin protects neurons against Abeta peptide toxicity. Brain Res 1152, 191-200.
37. Sudoh S, Frosch MP, Wolf BA (2002) Differential effects of proteases involved in intracellular degradation of amyloid beta-protein between detergent-soluble and -insoluble pools in CHO-695 cells. Biochemistry 41, 1091-1099.
38. Hemming ML, Selkoe DJ (2005) Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem 280, 37644-37650.
39. Turner AJ, Hooper NM (2002) The angiotensin-converting enzyme gene family: genomics and pharmacology. Trends Pharmacol Sci 23, 177-183.
40. Eckman EA, Adams SK, Troendle FJ, Stodola BA, Kahn MA, Fauq AH, Xiao HD, Bernstein KE, Eckman CB (2006) Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J Biol Chem 281, 30471-30478.
41. Bu G, Cam J, Zerbinatti C (2006) LRP in amyloid-beta production and metabolism. Ann N Y Acad Sci 1086, 35-53.
42. Deane R, Wu Z, Sagare A, Davis J, Du Yan S, Hamm K, Xu F, Parisi M, LaRue B, Hu HW, Spijkers P, Guo H, Song X, Lenting PJ, Van Nostrand WE, Zlokovic BV (2004) LRP/amyloid beta-peptide interaction mediates differential brain efflux of Abeta isoforms. Neuron 43, 333-344.
43. Mare S (2007) Copper complexing decreases the ability of amyloid beta peptide to cross the BBB and enter brain parenchyma. Peptides 28, 1424-1432.
44. Kuhnke D, Jedlitschky G, Grube M, Krohn M, Jucker M, Mosyagin I, Cascorbi I, Walker LC, Kroemer HK, Warzok RW, Vogelgesang S (2007) MDR1-P-Glycoprotein (ABCB1) mediates transport of Alzheimer's amyloid-beta peptides-implications for the mechanisms of Abeta clearance at the blood-brain barrier. Brain Pathol 17, 347-353.
45. Cirrito JR, Deane R, Fagan AM, Spinner ML, Parsadanian M, Finn MB, Jiang H, Prior JL, Sagare A, Bales KR, Paul SM, Zlokovic BV, Piwnica-Worms D, Holtzman DM (2005) P-glycoprotein deficiency at the blood-brain barrier increases amyloid-beta deposition in an Alzheimer disease mouse model. J Clin Invest 115, 3285-3290.
46. Selkoe DJ (2001) Alzheimer's disease results from the cerebral accumulation and cytotoxicity of amyloid-β protein. J Alzheimers Dis 3, 75-80.
47. Gouras GK, Almeida CG, Takahashi RH (2005) Intraneuronal Abeta accumulation and origin of plaques in Alzheimer's disease. Neurobiol Aging 26, 1235-1244.
48. Terzi E, Hölzemann G, Seelig J (1995) Self-association of beta-amyloid peptide (1-40) in solution and binding to lipid membranes. J Mol Biol 252, 633-642.
49. Wakabayashi M, Okada T, Kozutsumi Y, Matsuzaki K (2005) GM1 ganglioside-mediated accumulation of amyloid beta-protein on cell membranes. Biochem Biophys Res Commun 328, 1019-1023.
50. Kimura N, Yanagisawa K (2007) Endosomal accumulation of GM1 ganglioside-bound amyloid beta-protein in neurons of aged monkey brains. Neuroreport 18, 1669-1673.
51. Dai XL, Sun YX, Jiang ZF (2007) Protective effects of vitamin C against oxidative stress induced by Aβ(1-40). Cu(II) complexes. Chin J Biochem Mol Biol 23, 586-591.
52. Bisaglia M, Trolio A, Bellanda M, Bergantino E, Bubacco L, Mammi S (2006) Structure and topology of the non-amyloid-beta component fragment of human alpha-synuclein bound to micelles: implications for the aggregation process. Protein Sci 15, 1408-1416.
53. Rajendran L, Knobloch M, Geiger KD, Dienel S, Nitsch R, Simons K, Konietzko U (2007) Increased Abeta production leads to intracellular accumulation of Abeta in flotillin-1-positive endosomes. Neurodegener Dis 4, 164-170.
54. Verdier Y, Zarändi M, Penke B (2004) Amyloid beta-peptide interactions with neuronal and glial cell plasma membrane: binding sites and implications for Alzheimer's disease. J Pept Sci 10, 229-248.
55. Caltagarone J, Jing Z, Bowser R (2007) Focal adhesions regulate Abeta signaling and cell death in Alzheimer's disease. Biochim Biophys Acta 1772, 438-445.
56. Wright S, Malinin NL, Powell KA, Yednock T, Rydel RE, Griswold-Prenner I (2007) Alpha2beta1 and alphaVbeta1 integrin signaling pathways mediate amyloid-beta-induced neurotoxicity. Neurobiol Aging 28, 226-237.
57. Shaked GM, Kummer MP, Lu DC, Galvan V, Bredesen DE, Koo EH (2006) Abeta induces cell death by direct interaction with its cognate extracellular domain on APP (APP 597-624). FASEB J 20, 1254-1256.
58. Mandelkow E, von Bergen M, Biernat J, Mandelkow EM (2007) Structural principles of tau and the paired helical filaments of Alzheimer's disease. Brain Pathol 17, 83-90.
59. Stoothoff WH, Johnson GV (2005) Tau phosphorylation: physiological and pathological consequences. Biochim Biophys Acta 1739, 280-297.
60. Berriman J, Serpell LC, Oberg KA, Fink AL, Goedert M, Crowther RA (2003) Tau filaments from human brain and from in vitro assembly of recombinant protein show cross-beta structure. Proc Natl Acad Sci U S A 100, 9034-9038.
61. Skrabana R, Sevcik J, Novak M (2006) Intrinsically disordered proteins in the neurodegenerative processes: formation of tau protein paired helical filaments and their analysis. Cell Mol Neurobiol 26, 1085-1097.
62. Köpke E, Tung YC, Shaikh S, Alonso AC, Iqbal K, Grundke-Iqbal I (1993) Microtubule-associated protein tau. Abnormal phosphorylation of a non-paired helical filament pool in Alzheimer disease. J Biol Chem 268, 24374-24384.
63. Avila J (2006) Tau phosphorylation and aggregation in Alzheimer's disease pathology. FEBS Letters 580, 2922-2927.
64. Shimura H, Schwartz D, Gygi SP, Kosik KS (2004) CHIP-Hsc70 complex ubiquitinates phosphorylated tau and enhances cell survival. J Biol Chem 279, 4869-4876.
65. Rankin CA, Sun Q, Gamblin TC (2007) Tau phosphorylation by GSK-3beta promotes tangle-like filament morphology. Mol Neurodegener 2, 12.
66. Sato S, Tatebayashi Y, Akagi T, Chui DH, Murayama M, Miyasaka T, Planel E, Tanemura K, Sun X, Hashikawa T, Yoshioka K, Ishiguro K, Takashima A (2002) Aberrant tau phosphorylation by glycogen synthase kinase-3beta and JNK3 induces oligomeric tau fibrils in COS-7 cells. J Biol Chem 277, 42060-42065.
67. Dias-Santagata D, Fulga TA, Duttaroy A, Feany MB (2007) Oxidative stress mediates tau-induced neurodegeneration in Drosophila. J Clin Invest 117, 236-245.
68. Pevalova M, Filipcik P, Novak M, Avila J, Iqbal K (2006) Post-translational modifications of tau protein. Bratisl Lek Listy 107, 346-353.
69. Kins S, Crameri A, Evans DR, Hemmings BA, Nitsch RM, Gotz J (2001) Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice. J Biol Chem 276, 38193-38200.
70. Liu F, Iqbal K, Grundke-Iqbal I, Rossie S, Gong CX (2005) Dephosphorylation of tau by protein phosphatase 5: impairment in Alzheimer's disease. J Biol Chem 280, 1790-1796.
71. Rahman A, Grundke-Iqbal I, Iqbal K (2006) PP2B isolated from human brain preferentially dephosphorylates Ser-262 and Ser-396 of the Alzheimer disease abnormally hyperphosphorylated tau. J Neural Transm 113, 219-230.
72. Zheng WH, Bastianetto S, Mennicken F, Ma W, Kar S (2002) Amyloid beta peptide induces tau phosphorylation and loss of cholinergic neurons in rat primary septal cultures. Neuroscience 115, 201-211.
73. Blurton-Jones M, Laferla FM (2006) Pathways by which Abeta facilitates tau pathology. Curr Alzheimer Res 3, 437-448.
74. Bolmont T, Clavaguera F, Meyer-Luehmann M, Herzig MC, Radde R, Staufenbiel M, Lewis J, Hutton M, Tolnay M, Jucker M (2007) Induction of tau pathology by intracerebral infusion of amyloid-beta-containing brain extract and by amyloid-beta deposition in APP x Tau transgenic mice. Am J Pathol 171, 2012-2020.
75. Roberson ED, Scearce-Levie K, Yan F, Yua GQ, Mucke L (2006) Reducing endogenous tau prevents APP/Aβ-induced deficits in a mouse model of Alzheimer's disease. Alzheimers Dementia 2, S38.
76. Rapoport M, Dawson HN, Binder LI, Vitek MP, Ferreira A (2002) Tau is essential to beta-amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A 99, 6364-6369.
77. Shin RW, Ogino K, Shimabuku A, Taki T, Nakashima H, Ishihara T, Kitamoto T (2007) Amyloid precursor protein cytoplasmic domain with phospho-Thr668 accumulates in Alzheimer's disease and its transgenic models: a role to mediate interaction of Abeta and tau. Acta Neuropathol 113, 627-636.
78. Miranda S, Opazo C, Larrondo LF, Muñoz FJ, Ruiz F, Leighton F, Inestrosa NC (2006) The role of oxidative stress in the toxicity induced by amyloid beta-peptide in Alzheimer's disease. Prog Neurobiol 62, 633-648.
79. Butterfield DA, Perluigi M, Sultana R (2006) Oxidative stress in Alzheimer's disease brain: new insights from redox proteomics. Eur J Pharmacol 545, 39-50.
80. Onyango IG, Khan SM (2006) Oxidative stress, mitochondrial dysfunction, and stress signaling in Alzheimer's disease. Curr Alzheimer Res 3, 339-349.
81. Butterfield DA, Boyd-Kimball D (2005) The critical role of methionine 35 in Alzheimer's amyloid beta-peptide (1-42)-induced oxidative stress and neurotoxicity. Biochim Biophys Acta 1703, 149-156.
82. Hong WK, Han EH, Kim DG, Ahn JY, Park JS, Han BG (2007) Amyloid-beta-peptide reduces the expression level of mitochondrial cytochrome oxidase subunits. Neurochem Res 32, 1483-1488.
83. Melov S, Adlard PA, Morten K, Johnson F, Golden TR, Hinerfeld D, Schilling B, Mavros C, Masters CL, Volitakis I, Li QX, Laughton K, Hubbard A, Cherny RA, Gibson B, Bush AI (2007) Mitochondrial oxidative stress causes hyperphosphorylation of tau. PLoS ONE 2, e536.
84. Kadowaki H, Nishitoh H, Urano F, Sadamitsu C, Matsuzawa A, Takeda K, Masutani H, Yodoi J, Urano Y, Nagano T, Ichijo H (2005) Amyloid beta induces neuronal cell death through ROS-mediated ASK1 activation. Cell Death Differ 12, 19-24.
85. Atzori C, Ghetti B, Piva R, Srinivasan AN, Zolo P, Delisle MB, Mirra SS, Migheli A (2001) Activation of the JNK/p38 pathway occurs in diseases characterized by tau protein pathology and is related to tau phosphorylation but not to apoptosis. J Neuropathol Exp Neurol 60, 1190-1197.
86. Savage MJ, Lin YG, Ciallella JR, Flood DG, Scott RW (2002) Activation of c-Jun N-terminal kinase and p38 in an Alzheimer's disease model is associated with amyloid deposition. J Neurosci 22, 3376-3385.
87. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
88. Muyllaert D, Kremer A, Jaworski T, Borghgraef P, Devijver H, Croes S, Dewachter I, Van Leuven F (2008) Glycogen synthase kinase-3beta, or a link between amyloid and tau pathology? Genes Brain Behav 7 (Suppl 1), 57-66.
89. Engel T, Lucas JJ, Gómez-Ramos P, Moran MA, Avila J, Hernández F (2006) Cooexpression of FTDP-17 tau and GSK-3beta in transgenic mice induce tau polymerization and neurodegeneration. Neurobiol Aging 27, 1258-1268.
90. Leroy K, Yilmaz Z, Brion JP (2007) Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol 33, 43-55.
91. Lin YT, Cheng JT, Liang LC, Ko CY, Lo YK, Lu PJ (2007) The binding and phosphorylation of Thr231 is critical for Tau's hyperphosphorylation and functional regulation by glycogen synthase kinase 3beta. J Neurochem 103, 802-813.
92. Selenica ML, Jensen HS, Larsen AK, Pedersen ML, Helboe L, Leist M, Lotharius J (2007) Efficacy of small-molecule glycogen synthase kinase-3 inhibitors in the postnatal rat model of tau hyperphosphorylation. Br J Pharmacol 152, 959-979.
93. Peng XS, Chen XC, Huang JS, Zhu YG, Li YK, Zeng YQ (2004) Inducing abnormal phosphorylation of tau in hippocampal neurons after aggregated Aβ25-35 microinjected into hippocampus of rats. Chin J Neurol 37, 533-537.
94. Wang ZF, Li HL, Li XC, Zhang Q, Tian Q, Wang Q, Xu H, Wang JZ (2006) Effects of endogenous beta-amyloid overproduction on tau phosphorylation in cell culture. J Neurochem 98, 1167-1175.
95. Jin Y, Fan Y, Yan E-Z, Yang J, Zong Z-H, Qi Z-M (2007) Amyloid-β-protein fragment 25-35 down-regulates PI3K/Akt /p70S6K pathway in rat hippocampus in vivo. Chin J Pharmacol Toxicol 21, 90-98.
96. Dani JA, Bertrand D (2007) Nicotinic acetylcholine receptors and nicotinic cholinergic mechanisms of the central nervous system. Annu Rev Pharmacol Toxicol 47, 699-729.
97. Wang HY, Lee DH, D'Andrea MR, Peterson PA, Shank RP, Reitz AB (2000) beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem 275, 5626-5632.
98. Liu Q, Kawai H, Berg DK (2001) beta-Amyloid peptide blocks the response of alpha 7-containing nicotinic receptors on hippocampal neurons. Proc Natl Acad Sci U S A 98, 4734-4739.
99. Wang HY, Li W, Benedetti NJ, Lee DH (2003) Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem 278, 31547-31553.
100. Kihara T, Shimohama S, Sawada H, Honda K, Nakamizo T, Shibasaki H, Kume T, Akaike A (2001) alpha 7 nicotinic receptor transduces signals to phosphatidylinositol 3-kinase to block A beta-amyloid-induced neurotoxicity. J Biol Chem 276, 13541-13546.
101. Goedert M, Spillantini MG (2006) A century of Alzheimer's disease. Science 314, 777-781.